'''ANO3''' (Anoctamin 3) is a gene encoding a calcium-activated chloride channel protein. Mutations in ANO3 cause dystonia, particularly craniocervical dystonia, and the gene is considered a cause of DYT24. Beyond its well-established role in dystonia, ANO3 has emerging connections to neurodegeneration and may play important roles in Parkinson's Disease and related movement disorders 1.
ANO3 encodes a member of the anoctamin family of calcium-activated chloride channels. The protein is thought to function as a calcium-gated chloride channel, though its exact physiological role is still being elucidated. The anoctamin family comprises 10 members (ANO1-ANO10), all of which are predicted to have eight transmembrane domains and function as chloride channels or scramblases 2. ANO3 is predominantly expressed in the basal ganglia, cortex, and cerebellum, consistent with its role in movement disorders.
ANO3 is a 982-amino acid protein with the following structural features:
The protein's architecture is shared with other anoctamin family members, but ANO3 has unique properties that determine its tissue-specific function and disease involvement 3.
ANO3 functions as a calcium-activated chloride channel (CaCC) with the following properties:
In neurons, ANO3-mediated chloride flux affects neuronal excitability and synaptic transmission. The channel's role in regulating chloride homeostasis is particularly important in neurons where chloride gradients determine inhibitory versus excitatory responses 4.
ANO3 is expressed in several key brain regions relevant to movement disorders 5:
Within the brain, ANO3 expression is primarily neuronal:
ANO3 mutations cause DYT24, an autosomal dominant form of craniocervical dystonia 6. Key features include:
Clinical Presentation:
Genetics:
Pathophysiology: ANO3 mutations lead to altered channel function, affecting chloride homeostasis in basal ganglia neurons. This disrupts the normal inhibition/excitation balance, leading to involuntary movements 7.
ANO3 has emerging connections to Parkinson's Disease 8:
Dystonia in PD: ANO3 variants may modify the risk of dystonia in PD patients, particularly those on dopaminergic therapy.
Parkinsonism Plus: Some patients with ANO3 mutations present with parkinsonian features alongside dystonia.
Substantia Nigra: ANO3 expression in dopaminergic neurons suggests potential roles in PD pathogenesis.
Tremor: ANO3 variants have been associated with essential tremor and tremor-dystonia 9.
Myoclonus: ANO3 mutations can present with myoclonic features, particularly in combination with dystonia 10.
Epilepsy: Rare cases of ANO3-associated epilepsy have been reported 11.
ANO3 plays crucial roles in basal ganglia function that are relevant to both dystonia and neurodegeneration 12:
Direct Pathway: ANO3 in striatal MSNs affects the "go" pathway, influencing movement initiation
Indirect Pathway: Channel function in globus pallidus neurons modulates movement suppression
Nigral Circuitry: ANO3 in substantia nigra affects dopamine release and motor control
ANO3 regulates neuronal excitability through several mechanisms 13:
ANO3 is intimately connected to calcium signaling pathways 14:
While ANO3 is primarily known for causing dystonia, several connections to neurodegeneration exist:
Alzheimer's Disease: ANO3 expression may be altered in AD brains, potentially affecting neuronal calcium handling 15.
Parkinson's Disease: The channel's role in dopaminergic neurons suggests potential involvement in PD pathogenesis 16.
Huntington's Disease: ANO3 function in the striatum may be relevant to HD pathophysiology 17.
ANO3 interacts with several proteins relevant to its function:
ANO3 is regulated by several signaling pathways:
Treatment options for ANO3-related disorders include 18:
Botulinum toxin injections: Effective for blepharospasm and cervical dystonia
Deep brain stimulation (DBS): Target GPi or STN for refractory cases
Anticholinergic medications: Trihexyphenidyl can provide symptomatic relief
Dopamine-modulating agents: May help in some cases with parkinsonian features
Benzodiazepines: Clonazepam for anxiety and muscle relaxation
Modulating ANO3 activity is a potential therapeutic strategy:
Channel activators: Small molecules that enhance ANO3 function could normalize neuronal excitability
Channel inhibitors: Blocking excessive ANO3 activity may help in certain contexts
Gene therapy: AAV-mediated gene delivery to restore normal ANO3 function
Antisense oligonucleotides: Targeted knockdown of mutant alleles
Targeting ANO3 therapeutically faces several challenges:
Several animal models have been developed to study ANO3 function:
Knockout mice: Show altered motor behavior and neuronal excitability
Transgenic mice: Express human ANO3 mutations
Zebrafish models: Useful for developmental studies
In vitro models: Neuronal cultures from patient-derived cells
Key questions remaining about ANO3 include: